Eisai Stock Forecast, Price & News

+0.35 (+0.41 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume12,724 shs
Average Volume28,428 shs
Market Capitalization$25.30 billion
P/E Ratio61.37
Dividend Yield0.73%
30 days | 90 days | 365 days | Advanced Chart
Receive ESALY News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

Eisai logo

About Eisai

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.


Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
July 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.99 out of 5 stars

Medical Sector

1367th out of 2,214 stocks

Private Households Industry

197th out of 383 stocks

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Eisai (OTCMKTS:ESALY) Frequently Asked Questions

Is Eisai a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eisai stock.
View analyst ratings for Eisai
or view top-rated stocks.

What stocks does MarketBeat like better than Eisai?

Wall Street analysts have given Eisai a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eisai wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Eisai?

Eisai saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 6,800 shares, a decline of 74.4% from the June 15th total of 26,600 shares. Based on an average daily volume of 71,800 shares, the short-interest ratio is presently 0.1 days.
View Eisai's Short Interest

When is Eisai's next earnings date?

Eisai is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Eisai

How were Eisai's earnings last quarter?

Eisai Co., Ltd. (OTCMKTS:ESALY) issued its earnings results on Wednesday, May, 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company earned $1.39 billion during the quarter. Eisai had a net margin of 6.56% and a trailing twelve-month return on equity of 5.99%.
View Eisai's earnings history

How has Eisai's stock price been impacted by Coronavirus?

Eisai's stock was trading at $72.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ESALY stock has increased by 17.0% and is now trading at $85.30.
View which stocks have been most impacted by COVID-19

Is Eisai a good dividend stock?

Eisai pays an annual dividend of $0.62 per share and currently has a dividend yield of 0.73%. The dividend payout ratio of Eisai is 44.60%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eisai will have a dividend payout ratio of 36.47% next year. This indicates that Eisai will be able to sustain or increase its dividend.
View Eisai's dividend history.

What guidance has Eisai issued on next quarter's earnings?

Eisai issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $1.510-1.510 for the period. The company issued revenue guidance of $6.52 billion-6.52 billion.

Who are Eisai's key executives?

Eisai's management team includes the following people:
  • Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 74, Pay $1.25M)
  • Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 55, Pay $1.26M)
  • Dr. Lynn D. Kramer, VP & Chief Clinical Officer - Neurology Bus. Group (Age 71, Pay $1.74M)
  • Ms. Yanhui Feng, Sr. VP
  • Mr. Nadeem Sarwar, Pres
  • Mr. Ryohei Yanagi, Exec. VP & CFO (Age 59)
  • Ms. Sayoko Sasaki, Chief IR Officer & VP (Age 53)
  • Mr. Mitsuaki Tanaka, Chief Compliance Officer, Internal Control, Chief Information Security Officer & VP
  • Mr. Yasushi Okada, Representative Corp. Officer, COO, Industry Affairs, China Bus. & Data Integrity (Age 63)
  • Mr. Edward Stewart Geary, Sr. VP & Global Safety Officer (Age 59)

Who are some of Eisai's key competitors?

What is Eisai's stock symbol?

Eisai trades on the OTCMKTS under the ticker symbol "ESALY."

How do I buy shares of Eisai?

Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eisai's stock price today?

One share of ESALY stock can currently be purchased for approximately $85.30.

How much money does Eisai make?

Eisai has a market capitalization of $25.30 billion and generates $6.09 billion in revenue each year. The company earns $395.92 million in net income (profit) each year or $1.39 on an earnings per share basis.

How many employees does Eisai have?

Eisai employs 11,237 workers across the globe.

What is Eisai's official website?

The official website for Eisai is www.eisai.co.jp.

Where are Eisai's headquarters?

Eisai is headquartered at 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088.

How can I contact Eisai?

Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at 813-3817-3700.

This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.